News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer



9/30/2010 8:03:09 AM

MENLO PARK, Calif., Sept. 30 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer.

(Logo: http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100513/LA04336LOGO)

"We are very pleased to have Merdad as the new CEO of 3-V," said David M. Mott, 3-V's Executive Chairman, who is returning to his role as Chairman of the Board. "Merdad's extensive drug development experiences in different therapeutic areas, including infectious disease, coupled with his experience in respiratory medicine, make him an excellent choice to lead the team."

Prior to joining 3-V Biosciences, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas. Prior to his tenure with Genentech, Dr. Parsey worked at Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in Respiratory, Inflammation, Virology, Neurology, Ophthalmology and Gastrointestinal diseases. In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine. He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

"3-V has the opportunity, via the modulation of host-factor targets, to fundamentally change anti-viral treatment, and the company's founders, employees, and investors have created an environment to achieve this goal," said Dr. Parsey. "I am excited to join the 3-V team and help turn this exciting science into therapies that have the potential to improve the lives of patients."

About 3-V Biosciences

3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches. The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information


Stephen R. Brady

Vice President, Corporate Development, Strategy & Operations

650-561-8600



SOURCE 3-V Biosciences, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES